CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, and the Alliance for Clinical Research Excellence and Safety (ACRES), a multi-sector non-profit organization dedicated to building a stakeholder-driven integrated global system for clinical research, announced a strategic partnership.
CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, and the Alliance for Clinical Research Excellence and Safety (ACRES), a multi-sector non-profit organization dedicated to building a stakeholder-driven integrated global system for clinical research, announced a strategic partnership. The agreement will bring CluePoints into the ‘ACRES Alliance', a growing collaborative of excellence-minded, innovation-focused organizations from across the global clinical research enterprise, and will focus on improving data quality in clinical research by identifying potential risks at investigative sites.
The collaboration will initially explore opportunities for streamlining and improving the effectiveness of on-site monitoring visits by bringing CluePoints' CSM solutions to the ACRES shared global platform of integrated technologies, with the goal of improving the integrity of data and reducing trial costs. CluePoints and ACRES will also explore the potential of building the CSM solution into ACRES' global system to identify operational and performance problems in a trial before they actually happen, using historical databases of data quality and performance indicators from selected investigative sites. In addition, CluePoints will participate in ACRES' Foundation Initiatives related to quality management, site accreditation and standards, contributing to the “dynamic accreditation” process being developed by the Alliance.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.